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ABSTRACT  
Objective: The purpose of this study was to evaluate the extent and mechanism anti-cancer drug-loaded liposomes using wheat germ agglutinin as a 
guiding molecule.  
Methods: For the drug-loaded liposome synthesis, the thin film hydration method was used and the drug cisplatin was loaded during the synthesis 
and followed by the surface modification using wheat germ agglutinin (WGA) lectin. The developed system was confirmed based on transmission 
electron microscopy (TEM), atomic force microscopy (AFM), particle size (PS) analyzer, polydispersity index and Zeta Potential analyzer.  
Results: The results showed the surface modified by liposomes had the particle size 200±5 nm. The wheat germ agglutinin coated on the surface to 
liposome led to a reduction in zeta potential and drug entrapment efficiency while particle size increased. Plain liposomes containing cisplatin had 
less effect than WGA modified liposome on MCF-7 cell lines.  
Conclusion: The MTT studies indicated that the drug molecules were initially get delivered to the inside the cell. This formulation offered new 
simple approach and effectively kill the cells via targeting the nucleus.  
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INTRODUCTION 
The cisplatin is the anticancer drug and acts by forming platinum-DNA 
adducts that hinder rapidly dividing cells from duplicating their DNA 
for mitosis, thus lead to activations and enhancement of apoptosis. 
Apart from its potential therapeutic effects, it suffers from some 
limitations like low aqueous solubility, low bioavailability, and drug 
resistance. The cisplatin resistances mechanisms contribute to the 
multifactorial nature of the problem and mainly limit the extent of 
DNA damage, increased DNA adduct repair, and reduced drug uptake 
[1]. The less cisplatin accumulation in cancer cells may be occurred 
due to defects in the uptake process, inhibition in drug uptake, an 
increase in drug efflux. In this regard, some drug delivery based 
approaches are developed but drug conjugation to nanocarriers, 
cisplatin provides limited choices. The presence of two free ammonia 
ligands with amine ligand is highly chelated to the platinum metal ion 
and reduced amide bond formation with a carboxylic acid [2]. It has 
been found that the drug encapsulated liposomal system has the 
potential to protect the stability and integrity of therapeutic molecules 
and deliver the therapeutic agent to the desired target site. 
Incorporation of this therapeutic molecule in the lipid bilayer is a self-
assembly process and helps to reach drug molecule at the target site in 
control release manner because the local density of certain polymer 
residues on the liposome surface increases with the protonation of the 
polymer pendant groups, triggering the collapse of the liposomal 
membrane and release of its payloads [3].  
In the present work, lectinized liposomal system i. e lectin-
conjugated liposomal-system hypothesized as a drug carrier. In this 
system, WGA lectin was used as ligand because, it show a high 
transcytosis rate and binds to N-acetyl-D glucosamine and sialic acid 
of the plasma membrane of cancerous cells. WGA lectin recognized 
via specific glycosylation pattern i.e. O-glycans overexpressed at the 
surface of cancer cells, initiating their own uptake. This happens by 
forming plasma membrane invaginations, due to crosslinking 
properties of lectins with multivalent carbohydrates and 
glycoproteins expressed on the cancer cells [4]. In cancerous 
conditions, N-acetylgalactosamine linked by an alpha glycosidic 
bond to a serine or threonine (i.e. as an O-glycan), which are 
frequently overexpressed on the surface of cells. The mechanism 
involved GlcNAc glycosylation of O-serine (and O-threonine) that 
helps lectin to transverse and localize in the cytosol and nuclear 
receptors [5].  
In this study, the film hydration method was adopted to develop the 
liposomal formulation to load anti-cancer drug, cisplatin. For the 
specific nucleus delivery, the lectin was immobilized on the 
liposomal surface using N-hydroxysulfosuccinimide and 1-ethyl-3-
(3-dimethylamino propyl) carbodiimide hydrochloride (EDC–NHS) 
chemistry. The lectin coupling to the liposomes enhanced the 
cellular uptake and also guided the intracellular routing because the 
lectin has the ability to bind the gangliosides receptors of cells. The 
nucleus targeting was confirmed through microscopy-based imaging 
and anticancer activity using MCF-7 cell lines.  
MATERIALS AND METHODS 
Materials 
Cisplatin was obtained from Neon Laboratories Ltd., India. WGA lectin 
purchase from Medicago AB (Denmark). L-a-soya phosphatidylcholine 
(PC), stearylamine (SA), cholesterol (CHOL), Triton X-100, Sephadex 
G-25, N-hydroxysulfosuccinimide (NHS), 1-ethyl-3-(3-dimethylamino 
propyl) carbodiimide hydrochloride (EDC), Fluorescein isothiocyanate 
(FITC) were procured from Sigma Chemicals, St Louis. All other 
reagents and solvents used were of analytical grade. 
Preparation of the non-coupled liposomes (NCL) 
Cisplatin loaded conventional liposomes consisting lipids were 
prepared by a film hydration method as reported by Bangham et al. 
[6]. Briefly, 7:3:1 molar ratio of the lipids (PC: CHOL: SA) were 
dissolved in a chloroform and methanol mixture (2:1), and 
evaporating the solvent under reduced pressure in a rotary 
evaporator (Buchi type, York Sci. Co., Mumbai, India). The dried lipid 
film was hydrated with phosphate buffer saline (PBS, pH 7.4) 
consisting 1 mg/ml cisplatin followed by continuous vortexing of the 
flask for further 1 h to get multilamellar vesicles, which were then 
sonicated (Ultrasonicator, Imeco Ultrasonic, India) at amplitude 
60%, time 5 min and 2 pulse/s to get the unilamellar vesicles. 
Preparation of the WGA lectin coupled liposomes (WCL) 
WGA lectin was conjugated with liposomes by the method reported 
by Bogdanov et al., [7] with minor modifications. Briefly, 20 µl of 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 12, Issue 6, 2020 
Soni et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 60-64 
61 
0.25M EDC and 20 µl of 0.1M NHS were added to 200 µl of liposomes 
and incubated for 6 h. The unbound WGA lectin was removed by 
passing the liposomal suspension through the Sephadex G-25 spin 
column at 2000 rpm for 2 min. An aliquot of the clear supernatants 
obtained after centrifugation was lyophilized by using 0.5 M glucose 
as a cryoprotectant in an industrial freeze-drier (Genesis Pilot 
Lyophilizer) to achieve a preservable white powder. 
Characterizations  
The analysis of the particle size, PDI and zeta potential (ζ) of the 
liposomal formulation i. e NCL and WCL were carried out at 25 °C 
using a Zeta-sizer (NanoPlus AT zeta analyzer and Horiba 
instrument). The surface morphology of WCL was observed using 
TEM (TECNAI-12) by using the method previously reported [8]. The 
external morphology of WCL was further visualized by AFM 
(INTEGRA Prima, NT-MDT) in a semi-contact mode. Liposomes 
formulation as the suspension was diluted 10 times with distilled 
water. This diluted formulation was placed on a glass slide to form a 
dry film of suspension for observation [9]. The studying proteins 
and lipids, protein-lipids interactions by using Attenuated total 
reflection FTIR (ATR-FTIR) Bruker Tensor-37 using established 
methods [10]. 
% Entrapment efficiency (EE) 
% EE of NCL and WCL were determined by using the method 
described by Fry et al., 1978 [11]. The amount of drug unentrapped 
in the NCL and WCL was determined by passing the formulation 
through a Sephadex spin column, centrifuged at 3,000 rpm, and the 
eluent was separated and collected. Then collected NCL and WCL 
liposomes were lysed using 1 % Triton X-100. Mixture of 1.4 mg/ml 
of o-phenylenediamine (OPDA) solution, phosphate buffer pH 6.8, 
and dimethylformamide (DMF) (1 : 2 : 7) was added to each 
formulation i.e., NCL and WCL separately and heated at 100 °C for 10 
min in order to get the formation of a light green color. The UV 
absorption at 706 nm was measured by a UV-Vis spectrophotometer 
(Thermo Scientific, Orion AquaMate 7000) to estimate the 
concentration of cisplatin. A solution of cisplatin (10 μg/ml) in 
phosphate buffer pH 6.8 treated with the same procedure as above 
was used to prepare a calibration curve of cisplatin [12]. 
Entrapment ef�iciency (EE) = Amount of free drug
The total amount of drug
× 100 … (eq.1) 
In vitro drug release 
The In vitro drug release rates of cisplatin from both NCL and WCL 
formulations were investigated by using the dialysis tube (Sigma 
membrane, MW cut off 13 kDa). The dialysis membrane was soaked in 
double distilled water for 24 h before being utilized. First, both 
formulations were separately centrifuged (Remi, Mumbai, India) at 
3000 rpm for 2 min through Sephadex G-25 spin-column to remove 
the unentrapped drug. Subsequently, 1 ml of liposomal suspension of 
each formulation was taken into a dialysis tube and placed in a 
separate beaker containing 20 ml of PBS (pH 6.8). The beaker was 
placed over a magnetic stirrer, and release medium was maintained at 
37 °C with constant stirring at 100 rpm throughout the study. Samples 
were withdrawn at predetermined time intervals and replaced with 
the same volume of PBS (pH 6.8). The accumulated release of cisplatin 
was calculated (n=3) by determining the drug quantity. 
MTT assay 
In a 96-well plate (Corning, USA), 1 × 10 5cells were seeded per well in 
100 μL of Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS 
(fetal bovine serum) and allowed to adhere for 24 h. Then, media from 
the cells was aspirated and various concentrations of formulations were 
added. The DMEM with FBS was used as a control in each experiment 
and incubated for 24 h then [13]. Cells were then incubated with 3,4,5-
dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT assay) in sterile 
PBS (5 mg ml−1) for 4 h at 37 °C. After incubation, they were dissolved in 
100% DMSO [14] and absorbance(Abs) was measured using a 
microplate reader at 570 nm (Infinite Pro200, TECAN, Switzerland). The 
values thus obtained for the untreated control samples were equated to 
100% and relative percentage values for DS, NCL and WCL liposomes 
were calculated accordingly.  
% Cell viable cells = Abs treated cells−Abs blank(only media) 
Abs untreated cells −Abs blank (only media)
× 100 (eq.2) 
RESULTS AND DISCUSSION 
In the present work cisplatin bearing liposomal drug delivery 
system was prepared by thin-film hydrations method using PC, 
CHOL and SA in the ratio of 7:3:1. An optimum ratio of cholesterol 
with lipid is for required to maintain integrity and rigidity of vesicles 
[15]. In addition, platinum compounds are present in the core of 
cisplatin, carries a 2+or 4+charges, two NH3 groups and two C1 
groups that allow efficient liposome encapsulation [16, 17]. 
  
 
Fig. 1: Results of physico chemical characterizations (A) TEM analysis (B) atomic force microscopy: 3D views (C) Zeta potential (D) 
Particle size analysis (183.5±0.024 nm) 
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The developed formulations were further characterized for the 
size of the vesicles, Zeta potential, polydispersive index, % EE and 
surface morphology by TEM and AFM. The vesicle size (nm) of NCL 
and WCL formulations was found to be 154±.045 nm and 
183.5±0.024 nm, respectively. Importantly, size and composition 
of the liposome, play a significant role in reticuloendothelial 
system (RES) uptake and remove the liposomes with a diameter 
larger than 400 nm, whereas a liposome with a diameter around 
200 nm can remain in circulation for a long time [18]. The PDI 
value was found to be in less than 0.2 in both the cases i. e NCL and 
WCL, which indicates homogenous size distribution of liposomal 
formulation. The zeta potential of NCL was recorded as-
21.26±0.2.5 mV, while in the case of WCL it was-7.3±3.0 mV. The 
negative charge on NCL and WCL helps to prevent aggregation on 
storage and, thus, imparts stability to the liposomal dispersion. 
The % EE of liposomal preparation was 31.5±0.11% and 27.2±0.07 
% for NCL and WCL, respectively. Less encapsulation of cisplatin 
may be due to its water solubility. The surface morphology of WCL 
liposomal formulation was observed by TEM and AFM microscopy. 
The TEM images captured reveals the morphology of prepared 
liposomes. Fig. 1 A, shows the TEM image of the vesicles. In the 
images, the liposomes were shown in a spherical shape with a 
smooth surface. The AFM topographical imaging of the optimized 
formulations is depicted in fig. 1 B. AFM in the semi-contact mode 
allows the observation of the liposomal surface morphology 
without staining, labeling, and fixation. AFM also provides the 
measurement of the height, diameter and surface properties of the 
formulations as compared to TEM. The fig. clearly shows that the 
height and the diameter as appeared on the image are range 
wherein vesicle size was around 200 nm. 
  
 
Fig. 2: Fourier-transform infrared spectroscopy (FTIR) spectra results of (A) WGA coupled liposomes (B) WGA lectin (C) Plain liposome 
 
The FTIR analysis was performed to confirm the WGA lectin binding 
on the liposomes. The results were shown in fig. 2. Characteristics 
peaks of liposomal formulation at 2920 cm-1 and 3369 cm-1 were 
observed, which may be due to the presence of alkyl group and ester 
group in phosphatidylcholine, respectively. Wang et al. and 
Mudakavi et al. reported a similar peak pattern for the plain 
liposomal formulations[19, 20]. Fig. 2 B, shows the characteristics 
peaks of WGA lectin. According to Bonnin et al., two characteristics 
peaks of WGA, which correspond to Amide I bands, at 1700-1610 
cm-1, are principally due to C=O stretching vibrations with some N-H 
bending and C-H stretching vibrations while amide II bands, at 
1575-1480 cm-1, are principally due to N-H bending vibrations with 
some C≡N stretching vibrations [21]. The presence of peaks at 1640 
cm-1 and 1527 cm-1 (fig. 2 B) confirms the structure of WGA lectin. 
Fig. 2 A showed an intense peak at 1639 cm-1 due to amide C=O 
stretch. The disappearance of the WGA peaks i.e., 1640 cm-1 and 
1527 cm-1 (due to Amide I and Amide II) and the appearance of a 
new peak at 1639 cm-1 confirmed the formation of amide linkages 
between the NH2 group present on the liposomal surface and–COOH 
group of the WGA lectin. 
  
 
Fig. 3: In vitro drug release result of uncoupled liposomes (NCL) and lectin coupled liposomes (WCL) 
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In vitro drug release study was performed on two different 
formulations i. e NLC and WCL in phosphate buffer at pH 6.8 at room 
temperature. The NCL showed the fast releases of the drug as 
compared to WCL formulations, as shown in fig. 3. The amount of 
cisplatin released after 1 h was 25.6±1.73 % from NCL while it was 
16.8±1.63 % from WCL. After 8 h the cumulative drug release was 
found to be 90.40±0.53 % from NCL while it was 65.27±0.53 % from 
WCL. The maximum amount of drug was released within eight hours 
from the NCL, while in WCL formulation, slow and sustained release 
pattern was observed. This may be due to the secondary barrier 
effect because of the WGA coat over the surface of the liposomal 
formulations. This pattern of drug release clearly indicated that the 
drug was available over a protracted time in circulation and will 
provide an enhanced drug effect after administration. 
  
 
Fig. 4: Cell Cytotoxicity study result of (A) DS (B) NCL (D) WCL 
 
The MTT assay was performed using MCF-7 cell lines. The % cell 
viability formula of DS, NCL, and WCL, and individual dose-response 
curves were calculated using the % cell viability formula as shown in 
eq 2. The % cell viability of plain drug solutions was found to be more 
as compared to the lectin-modified formulation. The concentration 
range of 0.015–0.25 µg/ml was used for the calculation of % cell 
viability. The % control growth at 0.015 mg/ml was found to be 
51.39±1.6% for DS, 43.27±1.3% for NCL and 35.82±1.1% for WCL, 
which decreases as the concentration increases and found to be 
37.06±0.7% for free DS, 34.04±0.5% NCL and 31.06±0.1% for WCL at 
0.25 µg/ml (fig. 4). The results showed that the formulations were less 
toxic at 0.015 µg/ml. This may be due to low cellular absorption and 
internalizations of free drugs. In the case of lectinized formulations, 
the % cell viability was found to be less as compared to the plain DS 
and NCL formulation. This may be due to the anchoring of lectin over 
the liposomal surface that may facilitate their uptake via GlcNAc and 
sialic-acid receptors as well as due to avoidance of drug resistance 
(MDR). The reason for the cell death may be due to their 
transportation through endocytic compartments where they get 
coated with caveolin-1 protein, travels to the endoplasmic reticulum 
(ER), and finally reaching to the nucleus.  
CONCLUSION 
In this work, the lectin conjugated liposomal system was developed 
and their uptake path way was studied successfully. The studies 
confirmed the WCL lectin conjugated liposomes bind to the GlcNAc 
and sialic-acid receptors and it induce the drug uptake. The MTT 
assay suggested that the anti-cancer drug specifically caused the cell 
death and the death rates were mainly based on drug 
concentrations. The cell uptake and internalization studies indicated 
that the drug molecules were delivered to the cancerous cells.  
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